SCHEMBL4015445

SCHEMBL4015445

Cc1cc(Nc2cncc(Cl)n2)nn1C(=O)OC(C)(C)C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.37
JAK2 O60674 1/20 0.36
JAK1 P23458 1/20 0.36
CDK2 P24941 4/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
TP53 P04637 1/20 0.35
ALOX15 P16050 1/20 0.35
PTGER1 P34995 2/20 0.33
HSP90AA1 P07900 1/20 0.33
HSP90AB1 P08238 1/20 0.33
ROCK2 O75116 1/20 0.33
CHEK2 O96017 1/20 0.33
PRKACA P17612 1/20 0.33
RPS6KA3 P51812 1/20 0.33
PAK1 Q13153 1/20 0.33
ROCK1 Q13464 1/20 0.33
DYRK1A Q13627 1/20 0.33
PRKD2 Q9BZL6 1/20 0.33
LPAR1 Q92633 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4295678 0.86 MAPT (0.50) MAPTCDK2MEN1KMT2ATP53
SCHEMBL4303619 0.83 MAPT (0.54) MAPTCDK2MEN1KMT2ATP53
SCHEMBL4014355 0.83 MAPT (0.43) MAPTCDK2MEN1KMT2ATP53
SCHEMBL4169855 0.81 MAPT (0.34) MAPTCDK2MEN1KMT2ATP53
SCHEMBL16356861 0.80 STK17B (0.41) MAPTCDK2MEN1KMT2ATP53
SCHEMBL4295172 0.79 MAPT (0.42) MAPTMEN1KMT2ATP53ALOX15
SCHEMBL16356864 0.78 EGFR (0.40) MAPTCDK2MEN1KMT2ATP53
SCHEMBL14771765 0.76 ALK (0.40) MAPTALKSTK17BSTK17A
SCHEMBL4168093 0.75 MAPT (0.42) MAPTCDK2MEN1KMT2ATP53
SCHEMBL28629690 0.75 MAPT (0.37) MAPTMEN1KMT2ATP53ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090270418-A1 PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH SIGNAL PHARMACEUTICALS, LLC 2009-10-29 US disclosed
WO-2009089042-A1 PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH SIGNAL PHARMACEUTICALS, LLC (US) 2009-07-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270418-A1 PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH MAP3K1, MAP3K15, MAP3K5 MAPT 758/4885JAK2 39/4885JAK1 33/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.